Prospective randomized comparison of effect on coronary endothelial and renal function between febuxostat and benzbromarone in hyperuricemic patients with coronary artery disease: EFEF study.
Masami NishinoYasuyuki EgamiHitoshi NakamuraKohei UkitaAkito KawamuraYutaka MatsuhiroKoji YasumotoMasaki TsudaAkihiro TanakaNaotaka OkamotoYasuharu Matsunaga-LeeMasamichi YanoRyu ShuttaJun TanouchiPublished in: Health science reports (2022)
In conclusion, 8-months of febuxostat, XO inhibitor, does not significantly protect CEF but can protect the renal function including CIN in hyperuricemic patients with CAD compared to benzbromarone, non-XO inhibitor.